TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8700339
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam cinnamate
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml isotonic saline (S)
Study: 1833543
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lignocaine, 0.5% (L)
Study: 6227296
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (ASA/DPM)
Study: 30920059
Drug: Nd‐YAG 1064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd‐YAG 1064 nm laser treatment
Study: 23132800
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (20 mg lutein and 2 mg zeaxanthin)
Study: 20075646
Drug: Topiramate (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25‐50 mg/d)
Study: 18480522
Drug: IVPCA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVPCA using morphine
Study: 12051399
Drug: Amtolmetin guacyl
Normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin guacyl (AMG) 1,200 mg over the first 3 days and 600 mg/day thereafter
Study: 7733183
Drug: FOS-120 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS-120 group (120 mg/kg of body weight/day)
Study: 7733183
Drug: FOS-90 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS-90 group (90 mg/kg of body weight/day)
Study: 30024861
Drug: Adjuvanted varicella-zoster
Normalized name: varicella/zoster immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su)
Study: 30247596
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated zoster vaccine (ZV)
Study: 27836009
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200-1000 μg)
Study: 15757769
Drug: Intravenous flucloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flucloxacillin on induction followed by an oral placebo (Group A)
Study: 15757769
Drug: Intravenous flucloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flucloxacillin on induction followed by an oral flucloxacillin course (Group B)
Study: 15757769
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (Group C)
Study: 29191873
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (intervention group)
Study: 27924798
Drug: Carbonated tap
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonated tap water (placebo, 1 l/day for 6 weeks)
Study: 21352112
Drug: OPUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPUS treatment
Study: 12918553
Drug: Unwrapped hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwrapped hydroxyapatite implant
Study: 10945031
Drug: CMF combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF combination therapy
Study: 1893683
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Vacusac)
Study: 1893683
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Vacusac) after placebo
Study: 24599532
Drug: Vi capsular
Normalized name: typhoid vaccine VI capsular polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi capsular polysaccharide typhoid vaccine (25 μg, single dose)
Study: 21917503
Drug: Saline rinsing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline rinsing of one eye after wearing PureVision™ lenses pre-soaked in ReNu MultiPlus® solution for 1 hour
Study: 16085692
Drug: PS‐341 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS‐341 1.5 mg/m(2) i.v. bolus on days 1, 4, 8 and 11 (Arm A)
Study: 16085692
Drug: PS‐341 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS‐341 1.0 mg/m(2) plus gemcitabine 1,000 mg/m(2) i.v. on days 1 and 8 (Arm B)
Study: 1065757
Drug: Supervised daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised daily toothbrushing and flossing (10 sessions of instruction in plaque removal)
Study: 1065757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no instruction in oral hygiene procedures)
Study: 1065757
Drug: Supervised daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised daily toothbrushing and flossing
Study: 31738351
Drug: Yogurt group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt group (consumed 112 mL yogurt drink fermented with OLL1073R‐1 daily for 16 weeks)
Study: 21342748
Drug: Feed supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feed supplement
Study: 8436090
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (CLO) 25 ml daily for 8 weeks
Study: 30954948
Drug: Control group;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group; participants followed their regular preparation for the running event.
Study: 23036264
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 3 weeks
Study: 8683286
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 3 weeks
Study: 8892450
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and radiation dose or fractionation
Study: 1734985
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin treatment and home blood glucose monitoring
Study: 2429084
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 (20 mg t.i.d.)
Study: 22441743
Drug: Aclidinium 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 200 μg
Study: 22441743
Drug: Aclidinium 400
Normalized name: aclidinium 400 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 400 μg
Study: 18326596
Drug: High rTFA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High rTFA diet (10.2 g/2500 kcal)
Study: 18326596
Drug: iTFA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTFA diet (10.2 g/2500 kcal)
Study: 18326596
Drug: Moderate rTFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate rTFA diet (4.2 g/2500 kcal)
Study: 16436342
Drug: Nadifloxacin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadifloxacin 1% cream
Study: 16436342
Drug: Erythromycin 2%
Normalized name: ERYTHROMYCIN 2% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2% cream
Study: 14628252
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (1, 3, and 10 ng/kg/min for 45 min)
Study: 14628252
Drug: AT (1)-receptor
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT (1)-receptor antagonist (160 mg valsartan) prior to angiotensin II infusion
Study: 14628252
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion and AT (1)-antagonist administration
Study: 8731547
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment for PTSD
Study: 8731547
Drug: Treatment/wait list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment/wait list comparison group (weekly PTSD outpatient group therapy)
Study: 29744866
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling and twice‐weekly exercise classes
Study: 22121129
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg + MTX (Group 2)
Study: 21223649
Drug: Pressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure treatment group (custom pressure garment with 10% strain rate of pressure + 9 mm thick local pressure padding, worn more than 23 hours per day)
Study: 21223649
Drug: Pressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure treatment group (5.6 mm Hg pressure)
Study: 21223649
Drug: Pressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure treatment group (2.8 and 5.6 mm Hg pressure)
Study: 16052760
Drug: 35% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% phosphoric acid (0.5 ml)
Study: 8849298
Drug: Topical itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical itraconazole
Study: 8849298
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (Sporanox)
Study: 2236467
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of fluphenazine decanoate
Study: 484261
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for 8 days
Study: 484261
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for 15 days
Study: 21684425
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IIV)
Study: 30759228
Drug: Quadrivalent live‐attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent live‐attenuated influenza vaccine (LAIV)
Study: 24921418
Drug: Behaviorally oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally oriented treatment modality
Study: 24921418
Drug: Insight oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight oriented treatment modality
Study: 18298358
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy
Study: 24921418
Drug: Internet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet therapy
Study: 21628603
Drug: Aclidinium IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium IV doses (25-400 µg)
Study: 21628603
Drug: Inhaled aclidinium
Normalized name: aclidinium Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aclidinium (200 µg)
Study: 15370401
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin sodium suspension 2%
Study: 7850531
Drug: Hyperinsulinemic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic parenteral nutrition (1.44 U/kg/day regular human insulin)
Study: 29294501
Drug: 17-alpha hydroxyprogesterone
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg
Study: 23125943
Drug: Gauze dressing
Normalized name: Xeroform Petrolatum 1inch 8inch Gauze Dressing (Occlusive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gauze dressing daily for 7 days
Study: 23125943
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (5 mg/24 hours)
Study: 20021250
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week
Study: 8907343
Drug: Allopurinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (10 mg/kg/day during the first week and 15 mg/kg/day thereafter)
Study: 3321540
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline 7.5 mg twice daily
Study: 23376451
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg tid) plus Behavioral Weight Loss (BWL)
Study: 21454244
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel alternating between abdomen and upper arms/shoulders
Study: 17726409
Drug: Single-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intramuscular dexamethasone
Study: 11878525
Drug: Sitting for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting for 20 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Study: 10450749
Drug: GM-CSF, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF, 5 microg/kg/day from day 4 to day 8 of EMA chemotherapy
Study: 10450749
Drug: Placebo from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo from day 4 to day 8 of EMA chemotherapy
Study: 28068788
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum)
Study: 25555154
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 12 months
Study: 19474657
Drug: LAC group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC group: lansoprazole 30 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 14 days
Study: 19474657
Drug: BLTM group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLTM group: bismuth subcitrate 300 mg 4 times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Study: 15571316
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg once daily for 14 days
Study: 2472488
Drug: Subcutaneous interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon-beta serine (IFN‐beta ser)
Study: 2472488
Drug: Intravenous interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous interferon-beta serine (IFN‐beta ser)
Study: 2472488
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of interferon-beta serine (180 X 10(6) IU)
Study: 2472488
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of interferon-beta serine (45 X 10(6) IU)
Study: 30579569
Drug: BIKEN varicella-zoster
Normalized name: varicella/zoster immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIKEN varicella-zoster vaccine (BVZV) with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Study: 30579569
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Study: 21823420
Drug: Bushen Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Huoxue Recipe (BSHXR), one dose per day (taken in two times) for 8 weeks
Study: 21823420
Drug: Monopril 10
Normalized name: Monopril 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monopril 10 mg, once daily for 8 weeks (control group)
Study: 21823420
Drug: Monopril 10
Normalized name: Monopril 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monopril 10 mg, once daily (control group)
Study: 18465239
Drug: Renzapride (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride (1, 2, or 4 mg/day)
Study: 15018590
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIg) therapy
Study: 11168085
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir therapy
Study: 8325047
Drug: Sulodexide 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 50 mg enteric-coated tablets twice daily
Study: 8325047
Drug: Sulodexide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 100 mg enteric-coated tablets once daily
Study: 21166853
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin group (n=144, 70% of insulin users)
Study: 21166853
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin group (n=144)
Study: 31544802
Drug: Nutritional rehabilitation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation
Study: 12356214
Drug: Published reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Published reports of nine additional studies of single-agent MITO therapy for MS
Study: 12356214
Drug: Single-agent mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent mitoxantrone (MITO) therapy
Study: 7148735
Drug: Aspartame plus
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame plus monosodium L-glutamate (34 mg/kg body weight)
Study: 28248887
Drug: Sevoflurane with
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with remifentanil 1.5 μg/kg
Study: 28248887
Drug: Sevoflurane with
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with remifentanil 2.0 μg/kg
Study: 20883985
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 4 years
Study: 18726908
Drug: Pramipexole (D2/D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (D2/D3 agonist)
Study: 17522474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of US+CT+KUB
Study: 17522474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of US+CT
Study: 17522474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of KUB+CT
Study: 12322866
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic therapy
Study: 22152246
Drug: Liposomal albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal albendazole (L-ABZ)
Study: 22152246
Drug: L-ABZ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ABZ and T-ABZ
Study: 17118687
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment (200 microg/day for the first month, then 400 microg/day for men and 600 microg/day for women thereafter)
Study: 14552082
Drug: Lowering dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering dialysis fluid bicarbonate concentration from 37 mmol/l to 25 mmol/l
Study: 14552082
Drug: Adjusting dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusting dialysis fluid sodium concentration from 140 mmol/l to 132 mmol/l
Study: 4073858
Drug: Ceftriaxone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (80 mg/kg once daily after an initial dose of 100 mg/kg)
Study: 31033362
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEI)
Study: 26988368
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) with saline (tetracaine gel group)
Study: 26988368
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) with ropivacaine plus tetracaine gel (combination group)
Study: 18665163
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) added to paclitaxel (T) following epirubicin (E) and cyclophosphamide (C)
Study: 10584133
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 amifostine intravenously prior to high-dose radioiodine treatment
Study: 8561761
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment for hypochondriasis
Study: 1667511
Drug: Astragalus membranaceus
Normalized name: Astragalus membranaceus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus membranaceus (AM) intravenous 24 g/d infused into 5% glucose 250 ml
Study: 26858433
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) administered intranasally
Study: 20639355
Drug: Metformin (2×500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2×500 mg/day)
Study: 18520682
Drug: Other antiretroviral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiretroviral drugs
Study: 9932994
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% twice daily (n = 466)
Study: 9932994
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice daily (n = 371)
Study: 31591826
Drug: Ivabradine on
Normalized name: Ivabradine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine on top of guideline-directed medical therapy (GDMT)